"With this transaction, we will substantially strengthen two of our core businesses and create significant new options to increase value for shareholders."GSK said the agreement with Novartis "significantly exceeds GSK's returns criteria" and the transaction "would increase overall GSK revenues by £1.3bn to £26.9bn".Glaxo shareholders will get a £4bn capital return from the deal proceeds, the firm said. Source http://www.bbc.com/news/business-27107416
Could you please simplify the highlighted part talking about "returns criteria"?